Clinical results from a Phase IIb study have shown that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo in improving overall sleep efficiency in patients with primary insomnia.
18 June, 2010
Vital Therapies, Inc. (VTI) has announced that the first two subjects have been enrolled at King's College Hospital, London, in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe.
10 June, 2010